MOR - モ―ニングスタ― （MorphoSys AG） モ―ニングスタ―MORのチャート
MORの企業情報
| symbol | MOR |
|---|---|
| 会社名 | Morningstar Inc （モ―ニングスタ―） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | ― 金融（Financials） |
| 概要 | 事業概要 -- モ―ニングスタ―は、米国の投資リサ―チ会社。北米、ヨ―ロッパ、オ―ストラリア、アジアにおいて投資リサ―チ事業を展開。米国にて投資顧問、資産運用会社、退職金制度提供者・スポンサ―、個人投資家向けに商品およびサ―ビスを提供。またアジア、オ―ストラリア、カナダ、ヨ―ロッパ、中南米、南アフリカの投資家向けに設計され商品を提供する。 MorphoSys AG is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US. |
| 本社所在地 | 22 West Washington Street Chicago IL 60602 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 30803 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 4920人 |
| url | www.morningstar.com |
| nasdaq_url | https://www.nasdaq.com/symbol/mor |
| adr_tso | 10205648 |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 23.93 |
| 時価総額（marketcap） | 244221156.64 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
MORのテクニカル分析
MORのニュース
JPMorgan Downgrades MorphoSys AG to Underweight 2023/01/03 06:40:10 Investing.com
https://www.investing.com/news/pro/jpmorgan-downgrades-morphosys-ag-to-underweight-432SI-2971977
Goldman Sachs Reiterates Sell Rating on MorphoSys AG 2022/12/21 22:41:14 Investing.com
https://www.investing.com/news/pro/goldman-sachs-reiterates-sell-rating-on-morphosys-ag-432SI-2968883
MorphoSys CFO Sung Lee To Step Down In March 2023 2022/12/21 01:36:00 Finanz Nachrichten
MARTINSRIED (dpa-AFX) - MorphoSys AG (MOR) said that its Chief Financial Officer and Management Board member, Sung Lee, has decided to leave the company to move back to California for personal rea…
EQS-News: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023 2022/12/20 21:01:03 Wallstreet:Online
EQS-News: MorphoSys AG / Key word(s): Miscellaneous Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023 20.12.2022 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Media Release Planegg/Munich, Germany, December 20, 2022
MorphoSys Announces Longer-term Phase 2 Results On Pelabresib In Myelofibrosis 2022/12/12 06:06:00 Finanz Nachrichten
MARTINSRIED (dpa-AFX) - MorphoSys AG (MOR, MPSYY.PK) reported results from analyses of the ongoing MANIFEST study, a phase 2 clinical trial of pelabresib in patients with myelofibrosis, a type of …
Invitation to MorphoSys'' First Quarter 2022 Financial Results Conference Call on May 5, 2022 2022/04/28 20:45:00 Wallstreet:Online
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 28, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2022 on May 4, 2022 at 10:00 pm CEST (9:00 pm GMT; 4:00 pm EDT).MorphoSys'' Management team will host a …
DGAP-News: Invitation to MorphoSys'' First Quarter 2022 Financial Results Conference Call on May 5, 2022 2022/04/28 20:03:02 BORSE ONLINE
DGAP-News: MorphoSys AG / Key word(s): Quarter Results Invitation to MorphoSys'' First Quarter 2022 Financial Results Conference Call on May 5, 2022 28.04.2022 / 22:03 The issuer is solely responsible for the content of this announcement.
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale 2022/03/23 11:43:16 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J''s Janssen Unit Initiates Large-Scale Study of Psoriasis Drug In People of Color Johnson & Johnson''s (NYSE: JNJ ) Janssen unit announced the initiation of VISIBLE, a large-scale prospective clinical study dedicated to people of color living with moderate to severe plaque and/or scalp PsO. The study will further evaluate the efficacy and safety of Tremfya in people of color to generate additional data and provide valuable information about disease burden and the psoriatic disease patient journey in this population. MorphoSys, Incyte Announce Temporary Approval For Blood Cancer Combo Therapy In Switzerland MorphoSys AG (NASDAQ: MOR ) and partner Incyte Corporation (NASDAQ: INCY ) announced that the Swiss agency for therapeutic products has granted temporary approval for Minjuvi, in combination with Bristol-Myers Squibb Company''s (NYSE: BMY ) Revlimid, followed by Minjuvi monotherapy. The regimen is meant for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma, after at least one prior line of systemic therapy including an anti-CD20 antibody, who are not eligible for autologous stem cell transplant.
MorphoSys AG (MOR) CEO Jean-Paul Kress on Q4 2021 Results - Earnings Call Transcript 2022/03/17 16:24:14 Seeking Alpha
MorphoSys AG (MOR) Q4 2021 Earnings Call Transcript 2022/03/17 14:30:20 The Motley Fool
MOR earnings call for the period ending December 31, 2021.
MorphoSys AG: MorphoSys Announces Departure of Roland Wandeler 2021/11/09 21:32:00 FinanzNachrichten
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 9, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operati…
MorphoSys Announces Departure of Roland Wandeler 2021/11/09 21:21:11 Hosttech
(PR-inside.com) PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 9, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating Officer (COO) and member of the MorphoSys Management Board effective December 31, 2021 to pursue other opportunities. Following Dr. Wandeler''s departure, the commercial organization led by Joe Horvat, U.S. General Manager, will report directly to the Chief Executive Officer, Jean-Paul Kress, M.D. Dr. Wandeler joined MorphoSys in May 2020 and has been responsible for all commercialization activities worldwide, with a focus on strengthening U.S. operations and the launch of MorphoSys'' targeted immunotherapy ..
MorphoSys Presents Early Felzartamab Data From Autoimmune Kidney Disease Trial 2021/11/05 15:03:07 Business Insider Markets
MorphoSys AG (NASDAQ: MOR ) presented interim results from the M-PLACE Phase 1b/2a study with felzartamab at the 2021…
MorphoSys Presents Early Felzartamab Data From Autoimmune Kidney Disease Trial 2021/11/05 15:03:06 Benzinga
MorphoSys AG (NASDAQ: MOR ) presented interim results from the M-PLACE Phase 1b/2a study with felzartamab at the 2021 Annual Meeting of the American Society of Nephrology (ASN). Felzartamab is a fully human IgG1 monoclonal anti-CD38 antibody that can potentially deplete CD38-positive plasma cells that produce and secrete destructive autoantibodies. Depleting those … Full story available on Benzinga.com
MorphoSys AG: MorphoSys Presents Interim Results from M-PLACE Study with Felzartamab during American Society of Nephrology Annual Meeting 2021/11/04 20:32:00 FinanzNachrichten
Felzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathyPLANEGG/MUNICH, GERMANY / ACCESSWIRE / Novemb